Suzhou Fushilai Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 292.45 million compared to CNY 259.13 million a year ago. Revenue was CNY 297.35 million compared to CNY 272.36 million a year ago.

Net income was CNY 96.34 million compared to CNY 90 million a year ago. Basic earnings per share from continuing operations was CNY 1.051 compared to CNY 1.1221 a year ago. Diluted earnings per share from continuing operations was CNY 1.051 compared to CNY 1.1221 a year ago.